Profound Medical's TULSA Procedure to be featured at SRS Annual Meeting July 23-26

Profound Medical Corp.

TULSA Procedure highlighted in multiple presentations at SRS2026 in Fort Lauderdale, FL.
CAPTAIN randomized trial comparing TULSA vs. radical prostatectomy: primary safety outcomes presented July 24.
Real-world outcomes from multicenter post-market registry presented by UT Southwestern.
Profound selected as one of eight companies for Society of Incisionless Surgery plenary session.
Management to participate in investor session on July 22 moderated by Stifel and Wells Fargo analysts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.